Levothyroxine sodium hydrate | CAS#25416-65-3

MedKoo Cat#: 534603 | Name: Levothyroxine sodium hydrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levothyroxine sodium is a thyroid hormone.

Chemical Structure

Levothyroxine sodium hydrate

CAS#25416-65-3 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 534603

Name: Levothyroxine sodium hydrate

CAS#: 25416-65-3 (sodium hydrate)

Chemical Formula: C15H12I4NNaO5

Exact Mass: 816.6792

Molecular Weight: 816.87

Elemental Analysis: C, 22.06; H, 1.48; I, 62.14; N, 1.71; Na, 2.81; O, 9.79

Price and Availability

Size	Price	Availability
1g	USD 150.00	2 Weeks
2g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks
10g	USD 750.00	2 Weeks
25g	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

51-48-9 (free) 55-03-8 (sodium) 6106-07-6 (sodium pentahydrate) 25416-65-3 (sodium hydrate)

Synonym

Levothyroxine sodium hydrate

IUPAC/Chemical Name

L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt, hydrate

InChi Key

ANMYAHDLKVNJJO-LTCKWSDVSA-M

InChi Code

InChI=1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m0../s1

SMILES Code

N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O.[H]O[H].[Na+]

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Levothyroxine sodium is a thyroid hormone.

In vitro activity:

TBD

In vivo activity:

Tracheal responsiveness to methacholine and MDA concentration (p < 0.05) were decreased in AD (Alzheimer’s disease) rats treated with T4 compared to the AD group. Reference: Respir Physiol Neurobiol. 2020 Jun;277:103437. https://pubmed.ncbi.nlm.nih.gov/32259689/

Preparing Stock Solutions

The following data is based on the product molecular weight 816.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bavarsad K, Saadat S, Mohammadian Roshan N, Hadjzadeh MA, Boskabady MH. Effects of levothyroxine on lung inflammation, oxidative stress and pathology in a rat model of Alzheimer's disease. Respir Physiol Neurobiol. 2020 Jun;277:103437. doi: 10.1016/j.resp.2020.103437. Epub 2020 Apr 5. PMID: 32259689. 2. Bavarsad K, Hadjzadeh MA, Hosseini M, Pakdel R, Beheshti F, Bafadam S, Ashaari Z. Effects of levothyroxine on learning and memory deficits in a rat model of Alzheimer's disease: the role of BDNF and oxidative stress. Drug Chem Toxicol. 2020 Jan;43(1):57-63. doi: 10.1080/01480545.2018.1481085. Epub 2018 Jun 21. PMID: 29927658.

In vitro protocol:

TBD

In vivo protocol:

1: Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017 Jan;55(1):6-18. doi: 10.1007/s12020-016-1199-8. Epub 2016 Dec 16. PMID: 27981511. 2: Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D. Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. 2017 Feb;39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30. PMID: 28153426. 3: Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, Bender-Atik R, Agrawal R, Bhatia K, Edi-Osagie E, Ghobara T, Gupta P, Jurkovic D, Khalaf Y, MacLean M, McCabe C, Mulbagal K, Nunes N, Overton C, Quenby S, Rai R, Raine-Fenning N, Robinson L, Ross J, Sizer A, Small R, Tan A, Underwood M, Kilby MD, Boelaert K, Daniels J, Thangaratinam S, Chan SY, Coomarasamy A. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. N Engl J Med. 2019 Apr 4;380(14):1316-1325. doi: 10.1056/NEJMoa1812537. Epub 2019 Mar 23. PMID: 30907987. 4: Ianiro G, Mangiola F, Di Rienzo TA, Bibbò S, Franceschi F, Greco AV, Gasbarrini A. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci. 2014;18(4):451-6. PMID: 24610609. 5: Duntas LH, Jonklaas J. Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime. Adv Ther. 2019 Sep;36(Suppl 2):30-46. doi: 10.1007/s12325-019-01078-2. Epub 2019 Sep 4. PMID: 31485977; PMCID: PMC6822824. 6: Azran C, Porat D, Fine-Shamir N, Hanhan N, Dahan A. Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019 Feb;15(2):333-341. doi: 10.1016/j.soard.2019.01.001. Epub 2019 Jan 10. PMID: 30704913. 7: Chon DA, Reisman T, Weinreb JE, Hershman JM, Leung AM. Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. Thyroid. 2018 Apr;28(4):454-457. doi: 10.1089/thy.2017.0428. Epub 2018 Mar 28. PMID: 29589994; PMCID: PMC5905419. 8: Geer M, Potter DM, Ulrich H. Alternative schedules of levothyroxine administration. Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. PMID: 25694412. 9: Benvenga S, Carlé A. Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution. Adv Ther. 2019 Sep;36(Suppl 2):59-71. doi: 10.1007/s12325-019-01079-1. Epub 2019 Sep 4. PMID: 31485974; PMCID: PMC6822816. 10: Dhillon-Smith RK, Coomarasamy A. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Reply. N Engl J Med. 2019 Jul 11;381(2):190-191. doi: 10.1056/NEJMc1906509. PMID: 31291531.